...
首页> 外文期刊>Nature immunology >Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
【24h】

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

机译:小型抗病毒化合物通过TLR7 MyD88依赖性信号通路激活免疫细胞

获取原文
获取原文并翻译 | 示例
           

摘要

The imidazoquinoline compounds imiquimod and R-848 are low-molecular-weight immune response modifiers that can induce the synthesis of interferon-α and other cytokines in a variety of cell types. These compounds have potent anti-viral and anti-tumor properties; however, the mechanisms by which they exert their anti-viral activities remain unclear. Here we show that the imidazoquinolines activate immune cells via the Toll-like receptor 7 (TLR7)-MyD88-dependent signaling pathway. In response to the imidazoquinolines, neither MyD88- nor TLR7-deficient mice showed any inflammatory cytokine production by macrophages, proliferation of splenocytes or maturation of dendritic cells. Imidazoquinoline-induced signaling events were also abolished in both MyD88- and TLR7-deficient mice.
机译:咪唑喹啉化合物咪喹莫特和R-848是低分子量免疫应答调节剂,可诱导多种细胞类型中干扰素-α和其他细胞因子的合成。这些化合物具有有效的抗病毒和抗肿瘤特性。但是,它们发挥抗病毒活性的机制仍不清楚。在这里,我们显示咪唑并喹啉通过Toll样受体7(TLR7)-MyD88依赖性信号通路激活免疫细胞。响应咪唑并喹啉,MyD88和TLR7缺陷型小鼠均未显示出巨噬细胞,脾细胞增殖或树突状细胞成熟引起的任何炎性细胞因子产生。在MyD88和TLR7缺陷型小鼠中,咪唑喹啉诱导的信号转导事件也被消除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号